Efficacy of 2L®PAPI, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection

This website uses necessary technical cookies that are essential for the correct functioning of our website. In order to analyse statistics on the traffic and volume of visits, this website uses as well first-party and third-party audience measurement cookies. First-party cookies from Google Analytics are used to gather aggregate information such as the number of people visiting our website or which pages are the most visited. This helps us gather feedback so that we can improve our Micro-immunotherapy web site and better serve our users. Third-party cookies from platforms such as LinkedIn and Facebook are used to measure, optimize and build audiences for social media campaigns and analyse social media interaction.

When you first visit our website, you may choose whether to accept or refuse these cookies. Necessary cookies will still remain activated.